Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Fleseriu

Showing results (201-210 of 268) with videos related to

Pageof 27
Sort By:
Frontiers in Endocrinology|April 1, 2021
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor LigandsMaria Fleseriu, Mark Molitch, Alexander Dreval, et al.
Endocrine|November 26, 2013
Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trialLucio Vilar, Maria Fleseriu, Luciana Ansaneli Naves, et al.
European Journal of Endocrinology|October 6, 2025
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4Maria Fleseriu, Rosario Pivonello, André Lacroix, et al.
International Journal of Endocrinology|June 28, 2022
Development of a Novel Algorithm to Identify People with High Likelihood of Adult Growth Hormone Deficiency in a US Healthcare Claims DatabaseKevin C J Yuen, Anna Camilla Birkegard, Lewis S Blevins, et al.
Endocrine|April 28, 2021
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus PegvisomantSabrina Chiloiro, Antonella Giampietro, Felicia Visconti, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept studyXavier Bertagna, Rosario Pivonello, Maria Fleseriu, et al.
The Journal of Clinical Endocrinology and Metabolism|June 15, 2023
MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in AcromegalyMaria Fleseriu, Mark Molitch, Alexander Dreval, et al.
Pituitary|September 2, 2020
Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegalyElena V Varlamov, Matthew D Wood, Joao Prola Netto, et al.
The Lancet. Diabetes & Endocrinology|September 23, 2019
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trialMaria Fleseriu, Rosario Pivonello, Atanaska Elenkova, et al.
Pituitary|October 2, 2019
A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statementKen K Y Ho, Maria Fleseriu, John Wass, et al.
Pageof 27

Showing results (201-210 of 268) with videos related to

Sort By:
Pageof 27
Frontiers in Endocrinology|April 1, 2021
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor LigandsMaria Fleseriu, Mark Molitch, Alexander Dreval, et al.
Endocrine|November 26, 2013
Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trialLucio Vilar, Maria Fleseriu, Luciana Ansaneli Naves, et al.
European Journal of Endocrinology|October 6, 2025
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4Maria Fleseriu, Rosario Pivonello, André Lacroix, et al.
International Journal of Endocrinology|June 28, 2022
Development of a Novel Algorithm to Identify People with High Likelihood of Adult Growth Hormone Deficiency in a US Healthcare Claims DatabaseKevin C J Yuen, Anna Camilla Birkegard, Lewis S Blevins, et al.
Endocrine|April 28, 2021
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus PegvisomantSabrina Chiloiro, Antonella Giampietro, Felicia Visconti, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept studyXavier Bertagna, Rosario Pivonello, Maria Fleseriu, et al.
The Journal of Clinical Endocrinology and Metabolism|June 15, 2023
MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in AcromegalyMaria Fleseriu, Mark Molitch, Alexander Dreval, et al.
Pituitary|September 2, 2020
Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegalyElena V Varlamov, Matthew D Wood, Joao Prola Netto, et al.
The Lancet. Diabetes & Endocrinology|September 23, 2019
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trialMaria Fleseriu, Rosario Pivonello, Atanaska Elenkova, et al.
Pituitary|October 2, 2019
A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statementKen K Y Ho, Maria Fleseriu, John Wass, et al.
Pageof 27